150 related articles for article (PubMed ID: 15619026)
21. End-stage renal disease due to diabetes in racial/ethnic minorities and disadvantaged populations.
Lopes AA
Ethn Dis; 2009; 19(1 Suppl 1):S1-47-51. PubMed ID: 19484875
[TBL] [Abstract][Full Text] [Related]
22. Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study.
Keane WF; Zhang Z; Lyle PA; Cooper ME; de Zeeuw D; Grunfeld JP; Lash JP; McGill JB; Mitch WE; Remuzzi G; Shahinfar S; Snapinn SM; Toto R; Brenner BM;
Clin J Am Soc Nephrol; 2006 Jul; 1(4):761-7. PubMed ID: 17699284
[TBL] [Abstract][Full Text] [Related]
23. Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial.
Ishani A; Grandits GA; Grimm RH; Svendsen KH; Collins AJ; Prineas RJ; Neaton JD
J Am Soc Nephrol; 2006 May; 17(5):1444-52. PubMed ID: 16611715
[TBL] [Abstract][Full Text] [Related]
24. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
Arredondo A; Burke TA; Carides GW; Lemus E; Querol J
Rev Invest Clin; 2005; 57(3):399-405. PubMed ID: 16187699
[TBL] [Abstract][Full Text] [Related]
25. Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease.
Yao Q; Pecoits-Filho R; Lindholm B; Stenvinkel P
Scand J Urol Nephrol; 2004; 38(5):405-16. PubMed ID: 15764253
[TBL] [Abstract][Full Text] [Related]
26. Type-2 diabetes mellitus related cardiovascular risk: new options for interventions to reduce risk and treatment goals.
Hobbs FD
Atheroscler Suppl; 2006 Aug; 7(4):29-32. PubMed ID: 16822723
[TBL] [Abstract][Full Text] [Related]
27. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
[TBL] [Abstract][Full Text] [Related]
28. Effects of structured care by a pharmacist-diabetes specialist team in patients with type 2 diabetic nephropathy.
Leung WY; So WY; Tong PC; Chan NN; Chan JC
Am J Med; 2005 Dec; 118(12):1414. PubMed ID: 16378791
[TBL] [Abstract][Full Text] [Related]
29. Diabetic nephropathy.
Ritz E
Saudi J Kidney Dis Transpl; 2006 Dec; 17(4):481-90. PubMed ID: 17186681
[TBL] [Abstract][Full Text] [Related]
30. Clinical presentation of chronic hepatitis C in patients with end-stage renal disease and on hemodialysis versus those with normal renal function.
Hu KQ; Lee SM; Hu SX; Xia VW; Hillebrand DJ; Kyulo NL
Am J Gastroenterol; 2005 Sep; 100(9):2010-8. PubMed ID: 16128946
[TBL] [Abstract][Full Text] [Related]
31. Time trends in the epidemiology of renal transplant patients with type 1 diabetes mellitus over the last four decades.
Cao C; Hellermann JP; Weber M; Ambühl PM
Nephrol Dial Transplant; 2006 Mar; 21(3):770-5. PubMed ID: 16401627
[TBL] [Abstract][Full Text] [Related]
32. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients.
Steinke JM; Mauer M;
Pediatr Endocrinol Rev; 2008 Aug; 5 Suppl 4():958-63. PubMed ID: 18806710
[TBL] [Abstract][Full Text] [Related]
33. Current status of end-stage renal disease care in South Asia.
Jha V
Ethn Dis; 2009; 19(1 Suppl 1):S1-27-32. PubMed ID: 19484871
[TBL] [Abstract][Full Text] [Related]
34. ESRD in Guatemala and a model for preventive strategies: outlook of the Guatemalan Foundation for Children with Kidney Diseases.
Lou-Meda R
Ren Fail; 2006; 28(8):689-91. PubMed ID: 17162427
[TBL] [Abstract][Full Text] [Related]
35. Concomitant macro and microvascular complications in diabetic nephropathy.
Alwakeel JS; Al-Suwaida A; Isnani AC; Al-Harbi A; Alam A
Saudi J Kidney Dis Transpl; 2009 May; 20(3):402-9. PubMed ID: 19414942
[TBL] [Abstract][Full Text] [Related]
36. Metabolic syndrome and chronic kidney disease: a Japanese perspective on a worldwide problem.
Iseki K
J Nephrol; 2008; 21(3):305-12. PubMed ID: 18587718
[TBL] [Abstract][Full Text] [Related]
37. [Prevention and screening of chronic renal failure].
Bourel M; Ardaillou R
Bull Acad Natl Med; 2004; 188(8):1455-68. PubMed ID: 15918671
[TBL] [Abstract][Full Text] [Related]
38. Increasing body mass index and obesity in the incident ESRD population.
Kramer HJ; Saranathan A; Luke A; Durazo-Arvizu RA; Guichan C; Hou S; Cooper R
J Am Soc Nephrol; 2006 May; 17(5):1453-9. PubMed ID: 16597682
[TBL] [Abstract][Full Text] [Related]
39. End-stage renal disease in sub-Saharan Africa.
Naicker S
Ethn Dis; 2009; 19(1 Suppl 1):S1-13-5. PubMed ID: 19484867
[TBL] [Abstract][Full Text] [Related]
40. Strategies to retard the progression of chronic kidney disease.
Zandi-Nejad K; Brenner BM
Med Clin North Am; 2005 May; 89(3):489-509. PubMed ID: 15755464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
